Century Therapeutics, Inc. (IPSC) relative valueRV
IPSC's operating margin of -15.8% ranks in the 85th percentile of 16 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
Kresmion ranks IPSC against its industry peers from annual SEC filings and market-price snapshots.
Against 22 Biotechnology peers
| Metric | IPSC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 109M USD | 12.1M USD | 81st | 17 |
| Revenue YoY | n/a | n/a | n/a | 1 |
| Gross margin | n/a | n/a | n/a | 2 |
| Operating margin | -15.8% | -600.9% | 85th | 16 |
| Net margin | -8.8% | -392.9% | 79th | 16 |
| Return on equity | -6.0% | -67.4% | 81st | 17 |
| P / E | n/a | n/a | n/a | 1 |
| 1 year | n/a | n/a | n/a | n/a |
Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Fiscal period ending 2025-12-31. Prices as of 2026-10-28. Every fundamental figure is one full fiscal year from one filing. Nothing is trailing twelve months and nothing is converted between currencies. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above. 0001104659-26-026759
Peer set, 22 companies
SABS, NWBO, LCTX, FATE, ABEO, QTTB, RCKT, OCGN, CABA, BCYC, ARCT, LRMR, AGEN, VNDA, ANIK, IMRX, ACIU, IRD, PRLD, PROK, GLSI, SRZN
Left out: CUVL (no annual filing), VCRE (no annual filing), VOGX (no annual filing).
What could not be compared
- 56 The filer did not report this line in the filing used.
- 28 The denominator is zero or negative, so the ratio has no meaning.
- 23 The price series does not reach back to the start of this window.
- 4 Fewer than 5 peers carry a comparable value, so no median, quartile or percentile is published.
- 3 No annual filing (10-K, 20-F or 40-F) with fiscal-year figures.
- 1 This filer reports an ordinary share count and trades as a depositary receipt at a ratio Kresmion does not store, so price times shares would be wrong.
- 1 Reported in a different currency than the subject. A level in another currency is not comparable and is not converted here.
- 1 The latest close times the filed share count disagrees with the company's market cap by more than a split-sized factor, so price and the filing are not on one share basis.
Free account
Open the relative value desk with a free account
An account turns this page into a research desk: thirty-one metrics over the whole peer set instead of eight, the distribution behind each median, the metric's history against the peer band, an editable peer set, and the filing behind every cell. The table above stays free.
Cite this data
Every fundamental figure is the full fiscal year reported on one annual SEC filing (10-K, 20-F or 40-F), named by accession. Peers are the company's industry group: the GICS sub-industry where the company is GICS-classified, otherwise the data vendor's industry label (the two label sets are not merged). A median, quartile or percentile is published only when at least five peers carry a comparable value, and a peer reporting in another currency is excluded from a level rather than converted. P/E combines the market-price snapshot with annual earnings; one-year return uses market prices, dated separately above.
Upstream: SEC EDGAR XBRL company facts
Kresmion, "IPSC relative value, Kresmion", data as of 2026-03-12, https://kresmion.com/tools/relative-value/IPSC. Upstream data: SEC EDGAR XBRL company facts.
Link to this data (HTML):
<a href="https://kresmion.com/tools/relative-value/IPSC">IPSC relative value, Kresmion (Kresmion)</a>